Diagnostic and Prognostic Value of 18F-FDG PET/CT in Recurrent Germinal Tumor Carcinoma - Pierpaolo Alongi

(Length of discussion - 8 minutes)

Approximately 25% of testicular cancer patients present with advanced stage disease. Once chemotherapy is administered, radiologically-detectable residual masses are found in about 60% of these patients, making it difficult for a clinician to diagnose residual disease versus fibrosis or necrosis. Long-term survivable rates for these patients is generally favorable, however an accurate diagnostic tool capable of predicting survival is key to ensuring the best treatment strategy. Dr. Pierpaolo Alongi discusses his study to evaluate the performance of 18F-FDG PET/CT during the restaging process, the effect of treatment decisions, and the prognostic value of FDG-PET/CT in patients with suspected recurrent GTC after treatment.

Related Content on 18F-FDG PET/CT:

ASCO 2017: FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry.

18F-FDG PET/CT and PET/MRI perform equally well in cancer patients: Evidence from studies in more than 2300 patients.

Dr. Pierpaolo Alongi is a Nuclear Medicine Physician and oversees PET and scientific activities at the Unit of Nuclear Medicine - Fondazione Istituto G.Giglio Cefalù, Italy. Dr. Alongi has also served as the National Coordinator of Young AIMN group (Associazione Italiana di Medicina Nucleare e Imaging Molecolare) since 2013.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.